Abstract
Introduction Lassa fever is an acute viral haemorrhagic fever that poses a substantial public health security threat in West Africa. Due to its non-specific clinical manifestations and the absence of a reliable point-of-care test, diagnosis could be delayed, leading to severe complications and mortality during epidemics. This systematic review aimed to determine the clinical outcomes of LF in West Africa.
Methods A systematic review and meta-analyses were performed by conducting an extensive online search using PubMed, Web of Science, Scopus, CINAHL, and Google Scholar (PROSPERO protocol CRD42024587426). Only articles written in English were included in publications from 2014 to 2024. The analysis followed PRISMA guidelines. The mortality rate of LF was pooled using a random effects model.
Results We included 19 studies that contained data from 4177 patients hospitalized with LF of any age. Most of the studies were of retrospective cohort (16/19; 84.2%) study design and were predominantly conducted in Nigeria (16/19; 84.2%). The mortality rate was highest in a Sierra Leonean study (63.0%), whereas group-based analysis among the Nigerian studies identified Owo as having the highest mortality rate of 13% (95% CI: 06-23; I2 =98%). The pooled LF mortality rate was 19% (95% confidence interval [CI]:10-32). The most common complications of LF are acute kidney injury (AKI) at a pooled proportion of 19% (95% CI; 13-26; I2=89%)), followed by abnormal bleeding at a pooled proportion of 17% (95% CI; 9-30; I2=98%), and CNS manifestations at a pooled proportion of 15% (95% CI; 6-32; I2=98%)).
Conclusion With one out of every five hospitalized Lassa Fever patients likely to die in West Africa, accelerating the development of rapid diagnostic tests, licensed vaccines, and novel therapeutics is crucial. Strengthening community engagement, risk communication, and healthcare worker training will enhance early diagnosis and effective case management thereby reducing mortality and severe complications.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
Funding Statement
Yes. This study was funded by the Nigerian Institute of Medical Research Foundation[Grant Number NF-GMTP-24-152809].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos